Assurance in ADC Therapy for HER2+ or HER2-Low mBC

To conclude this series, our seasoned panel describes how clinical trial and practical experiences with antibody drug conjugate therapy for mBC instill their confidence in this therapy.

Video Library —November 27, 2023
Tajuana Bradley, MS, FNP-BC
Nurse Practitioner
Georgia Cancer Specialists
Atlanta, GA
Ryan Haumschild, PharmD, MS, MBA
Director of Pharmacy Services
Emory Healthcare and Winship
Cancer Institute
Atlanta, GA
Abbey J. Kaler, MS, APRN, FNP-C
University of Texas MD Anderson Cancer Center
Houston, TX
Susie Ulloa, RN, OCN, ONN-CG
Oncology Nurse Navigator
APT. Inc.
Gainesville, FL

Interview with the Innovators Presents:
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC

As the breast cancer landscape continues to evolve with new research, it is imperative for advance practice providers and nurse navigators to have a comprehensive understanding of the disease state and side effect management. This educational series is intended to enhance the knowledge of advanced practice providers and navigators around a treatment option now available to a new patient population with mBC. The publishers of JONS and JHOP are pleased to present this 6-part video series featuring expert commentary:

Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: January 10, 2024

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State